Valencia, CA – October 15, 2013 – SetPoint Medical, a biomedical technology company developing neuromodulation therapies for inflammatory diseases, announced today that it has been named
by FierceMedicalDevices as one of 2013’s Fierce 15 device and diagnostic companies, designating it as one of the most promising private companies in the med tech space. This is FierceMedicalDevices’ second annual Fierce 15 selection.
“These companies represent some of the best and brightest in the device and diagnostics industries
today,” FierceMedicalDevices Editor Damian Garde said. “They’ll be producing big things in the months ahead.”
“We are honored to be selected as a Fierce 15 company,” said Anthony Arnold, chief executive officer of SetPoint Medical. “SetPoint embodies the innovative spirit of this award as we advance our breakthrough approach, using neuromodulation to provide physicians and patients with new and innovative treatments for rheumatoid arthritis (RA), Crohn’s disease and other autoimmune and inflammatory diseases.”
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition.
SetPoint is developing a novel proprietary bioelectronic medicine platform to treat a variety of inflammation- mediated autoimmune diseases. In contrast to immunosuppressive drugs, this neuromodulation therapy uses an implantable pulse generator to stimulate the vagus nerve, activating the body’s natural Inflammatory Reflex to produce a systemic anti-inflammatory effect.
An internationally recognized newsletter reaching more than 30,000 medical device and diagnostics industry professionals, FierceMedicalDevices provides subscribers with an authoritative analysis of the day’s top stories. Every year, FierceMedicalDevices evaluates dozens of private companies from around the world for its annual Fierce 15 list, which is based on factors including technology strength, partnerships, venture backers and a competitive market position.
A complete list of “Fierce 15” companies – the online newsletter’s second annual selection – is available online at FierceMedicalDevices.com.
FierceMedicalDevices is the med tech industry’s daily monitor – a free email newsletter and web resource providing the latest news, articles and resources related to M&A, clinical trials, FDA approval and regulation, and more. Signing up is free.
About SetPoint Medical
SetPoint Medical is a privately held biomedical technology company dedicated to treating patients with debilitating inflammatory diseases using proprietary implantable neuromodulation devices. SetPoint’s approach is intended to offer patients and providers an alternative approach for the treatment of RA and other chronic inflammatory diseases with less risk and cost than drug therapy.
SetPoint’s novel platform consists of an implantable miniature neuromodulation device, wireless charger and iPad prescription pad application. The system uses vagus nerve stimulation to activate the body’s natural Inflammatory Reflex, which produces a potent systemic anti-inflammatory effect. The company presented positive results from a first-in-human open-label proof-of-concept trial in rheumatoid arthritis at the American College of Rheumatology annual meeting in November 2012. The results confirmed extensive preclinical studies and showed clinical efficacy comparable to leading immunosuppressive drugs. SetPoint is headquartered in Valencia, Ca., and current investors in the company include Morgenthaler Ventures, Foundation Medical Partners, Topspin Partners, Covidien Ventures, Action Potential Venture Capital Limited, the GlaxoSmithKline (GSK) new strategic venture capital fund for bioelectronic medicines and technologies, and Boston Scientific. For more information, visit www.setpointmedical.com.